Wilson T A, Romano C, Liang J, Nicolosi R J
The Center for Chronic Disease Control, Department of Health and Clinical Science, University of Massachusetts Lowell, 01854, USA.
Metabolism. 1998 Aug;47(8):959-64. doi: 10.1016/s0026-0495(98)90351-1.
Cholazol H (Alpha-Beta Technology, Worcester, MA), a chemically functionalized, insoluble dietary fiber with bile acid sequestrant properties, was studied in 30 male F1 B Golden Syrian hamsters for its effect on plasma lipid concentrations and early atherogenesis in experiment 1. In experiment 2, 30 male Golden Syrian hamsters were studied for the effects on plasma lipids and fecal excretion of bile acids. In experiment 1, three groups of 10 hamsters each were fed a chow-based hypercholesterolemic diet supplemented with 5% coconut oil and 0.1% cholesterol for 6 weeks. After 6 weeks, hamsters were continued on the diet with either 0% drug (hypercholesterolemic diet [HCD]), 0.5% cholestyramine (CSTY), or 0.5% Cholazol H for 8 weeks. Fasting plasma lipids were measured at weeks 6, 10, and 14, and early atherosclerosis (fatty streak formation) was measured at week 14. Relative to HCD, CSTY and Cholazol H significantly lowered plasma total cholesterol (TC) (-37%, P < .03, and -30%, P < .04, respectively) and plasma very-low and low-density lipoprotein-cholesterol (nonHDL-C) (-45%, P < .02, and -36%, P < .03, respectively) with no significant effects on plasma HDL-C or triglycerides (TG). Despite similar reductions in nonHDL-C, only Cholazol H significantly prevented early atherosclerosis (-38%, P < .02) relative to HCD. In experiment 2, three groups of 10 hamsters each were fed a chow-based hypercholesterolemic diet supplemented with 10% coconut oil and 0.05% cholesterol and either 0% drug HCD, 0.5% CSTY, or 0.5% Cholazol H for 4 weeks. Fasting plasma lipids were measured at weeks 2 and 4, and fecal bile acids were measured at week 4. Both Cholazol H and CSTY were equally effective in significantly lowering plasma TC (-16%, P < .003, and -13%, P < .01, respectively) and nonHDL-C (-22%, P < .004, and -18%, P < .02, respectively), with no significant effect on HDL-C and TG relative to HCD. Cholazol H and CSTY produced a significantly greater concentration of fecal total bile acids (39%, P < .001, and 28%, P < .002, respectively) relative to HCD. Also, there was a 48% (P < .002) and 65% (P < .001) greater fecal concentration of cholic acid (CA) for Cholazol H-treated hamsters compared with HCD- and CSTY-treated hamsters, respectively. Cholazol H also significantly increased fecal concentration of deoxycholic acid (DCA; 56%, P < .02) compared with HCD. In summary, Cholazol H is as effective as CSTY for prevention of diet-induced hypercholesterolemia and early atherosclerosis in hamsters.
在实验1中,对30只雄性F1B金色叙利亚仓鼠研究了具有胆汁酸螯合特性的化学功能化不溶性膳食纤维Cholazol H(Alpha-Beta Technology公司,马萨诸塞州伍斯特)对血浆脂质浓度和早期动脉粥样硬化形成的影响。在实验2中,对30只雄性金色叙利亚仓鼠研究了其对血浆脂质和胆汁酸粪便排泄的影响。在实验1中,将每组10只仓鼠分为三组,给它们喂食添加了5%椰子油和0.1%胆固醇的基于饲料的高胆固醇饮食,持续6周。6周后,仓鼠继续食用含有0%药物(高胆固醇饮食[HCD])、0.5%考来烯胺(CSTY)或0.5% Cholazol H的饮食,持续8周。在第6、10和14周测量空腹血浆脂质,并在第14周测量早期动脉粥样硬化(脂肪条纹形成)。相对于HCD,CSTY和Cholazol H显著降低了血浆总胆固醇(TC)(分别降低37%,P <.03,和30%,P <.04)以及血浆极低密度和低密度脂蛋白胆固醇(非HDL-C)(分别降低45%,P <.02,和36%,P <.03),对血浆高密度脂蛋白胆固醇(HDL-C)或甘油三酯(TG)无显著影响。尽管非HDL-C有类似程度的降低,但相对于HCD,只有Cholazol H显著预防了早期动脉粥样硬化(降低38%,P <.02)。在实验2中,将每组10只仓鼠分为三组,给它们喂食添加了10%椰子油和0.05%胆固醇的基于饲料的高胆固醇饮食,并分别添加0%药物HCD、0.5% CSTY或0.5% Cholazol H,持续4周。在第2和4周测量空腹血浆脂质,并在第4周测量粪便胆汁酸。Cholazol H和CSTY在显著降低血浆TC(分别降低16%,P <.003,和13%,P <.01)和非HDL-C(分别降低22%,P <.004,和18%,P <.02)方面同样有效,相对于HCD,对HDL-C和TG无显著影响。相对于HCD,Cholazol H和CSTY使粪便总胆汁酸浓度显著升高(分别升高39%,P <.001,和28%,P <.002)。此外,与HCD处理的仓鼠和CSTY处理的仓鼠相比,Cholazol H处理的仓鼠粪便中胆酸(CA)浓度分别高出48%(P <.002)和65%(P <.001)。与HCD相比Cholazol H还显著提高了粪便中脱氧胆酸(DCA)的浓度(升高56%,P <.02)。总之,在预防仓鼠饮食诱导的高胆固醇血症和早期动脉粥样硬化方面,Cholazol H与CSTY同样有效。